SCHEMBL7875129

SCHEMBL7875129

N#Cc1ccc(C(c2ccc(C#N)cc2)N2CCNCC2)cc1

nearest known ligand 0.87

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 10/20 0.87
CYP19A1 P11511 6/20 0.62
CYP2D6 P10635 1/20 0.62
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
OPRM1 P35372 1/20 0.50
OPRK1 P41145 1/20 0.50
OPRL1 P41146 1/20 0.50
CYP2C19 P33261 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP11B1 P15538 1/20 0.44
TSHR P16473 1/20 0.44
CYP11B2 P19099 1/20 0.44
USP2 O75604 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6797327 0.92 OPRD1 (0.97) OPRD1CYP19A1CYP2D6MEN1KMT2A
SCHEMBL31647252 0.82 OPRD1 (0.62) OPRD1CYP19A1CYP2D6MEN1KMT2A
SCHEMBL23033972 0.79 OPRD1 (0.58) OPRD1CYP19A1CYP2D6MEN1KMT2A
SCHEMBL1137956 0.77 CYP2D6 (1.00) OPRD1CYP19A1CYP2D6MEN1KMT2A
SCHEMBL8963511 0.77 CYP2D6 (0.67) OPRD1CYP19A1CYP2D6MEN1KMT2A
SCHEMBL15100999 0.77 CYP2D6 (0.67) OPRD1CYP19A1CYP2D6MEN1KMT2A
SCHEMBL336219 0.77 CYP2D6 (0.67) OPRD1CYP19A1CYP2D6MEN1KMT2A
SCHEMBL219432 0.76 MEN1 (1.00) OPRD1CYP19A1CYP2D6MEN1KMT2A
SCHEMBL2794662 0.76 MEN1 (1.00) OPRD1CYP19A1CYP2D6MEN1KMT2A
Hydrochloric Acid SCHEMBL7006476 0.75 MEN1 (0.96) OPRD1CYP19A1CYP2D6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 WO disclosed
US-H2007-H1 INSECTICIDES FMC CORPORATION 2001-12-04 US disclosed
WO-1997026252-A1 INSECTICIDAL N-HETEROCYCLYLALKYL- OR N-[(POLYCYCLYL)-ALKYL]-N'-SUBSTITUTED PIPERAZINES FMC CORPORATION (US) 1997-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL OPRD1 1514/4885CYP19A1 1123/4885CYP2D6 727/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL OPRD1 1514/4885CYP19A1 1123/4885CYP2D6 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.